263 related articles for article (PubMed ID: 8618462)
1. Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia.
Tallman MS
Leukemia; 1996 Apr; 10 Suppl 1():S12-5. PubMed ID: 8618462
[TBL] [Abstract][Full Text] [Related]
2. Differentiating therapy in acute myeloid leukemia.
Tallman MS
Leukemia; 1996 Aug; 10(8):1262-8. PubMed ID: 8709629
[TBL] [Abstract][Full Text] [Related]
3. Differentiating therapy in acute myeloid leukemia.
Tallman MS
Leukemia; 1996 Jun; 10 Suppl 2():s33-8. PubMed ID: 8649051
[TBL] [Abstract][Full Text] [Related]
4. All-trans-retinoic acid in acute promyelocytic leukemia and its potential in other hematologic malignancies.
Tallman MS
Semin Hematol; 1994 Oct; 31(4 Suppl 5):38-48. PubMed ID: 7831584
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
[TBL] [Abstract][Full Text] [Related]
6. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
7. Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond.
Tallman MS
Leukemia; 1998 Sep; 12 Suppl 1():S37-40. PubMed ID: 9777894
[TBL] [Abstract][Full Text] [Related]
8. [All-trans retinoic acid (Tretinoin)].
Ohno R
Gan To Kagaku Ryoho; 1997 Apr; 24(6):741-6. PubMed ID: 9126315
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of acute promyelocytic leukemia by all trans retinoic acid].
Castaigne S; Degos L
C R Seances Soc Biol Fil; 1995; 189(4):515-20. PubMed ID: 8564565
[TBL] [Abstract][Full Text] [Related]
10. Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma.
Masetti R; Biagi C; Zama D; Vendemini F; Martoni A; Morello W; Gasperini P; Pession A
Adv Ther; 2012 Sep; 29(9):747-62. PubMed ID: 22941525
[TBL] [Abstract][Full Text] [Related]
11. In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia.
Cornic M; Delva L; Castaigne S; Lefebvre P; Balitrand N; Degos L; Chomienne C
Leukemia; 1994; 8 Suppl 2():S16-9. PubMed ID: 7815831
[TBL] [Abstract][Full Text] [Related]
12. All-trans-retinoic acid in acute promyelocytic leukemia.
Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Ogden A; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
N Engl J Med; 1997 Oct; 337(15):1021-8. PubMed ID: 9321529
[TBL] [Abstract][Full Text] [Related]
13. All-trans-retinoic acid treatment and retinoic acid receptor alpha gene rearrangement in acute promyelocytic leukemia: a model for differentiation therapy.
Degos L
Int J Cell Cloning; 1992 Mar; 10(2):63-9. PubMed ID: 1312109
[TBL] [Abstract][Full Text] [Related]
14. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
[TBL] [Abstract][Full Text] [Related]
15. In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells.
Calabresse C; Barbey S; Venturini L; Balitrand N; Degos L; Fenaux P; Chomienne C
Leukemia; 1995 Dec; 9(12):2049-57. PubMed ID: 8609716
[TBL] [Abstract][Full Text] [Related]
16. Acute promyelocytic leukemia (AML-M3)--Part 1: Pathophysiology, clinical diagnosis, and differentiation therapy.
Randolph TR
Clin Lab Sci; 2000; 13(2):98-105. PubMed ID: 11066455
[TBL] [Abstract][Full Text] [Related]
17. All-trans retinoic acid potentiates megakaryocyte colony formation: in vitro and in vivo effects after administration to acute promyelocytic leukemia patients.
Visani G; Zauli G; Tosi P; Ottaviani E; Gibellini D; Manfroi S; Celeghini C; Pagliarini C; Bassini A; Tura S
Leukemia; 1994 Dec; 8(12):2183-7. PubMed ID: 7528859
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with all-trans-retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage.
Dombret H; Sutton L; Duarte M; Daniel MT; Leblond V; Castaigne S; Degos L
Leukemia; 1992 Dec; 6(12):1237-42. PubMed ID: 1453767
[TBL] [Abstract][Full Text] [Related]
19. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
20. [Induction therapy of acute promyelocytic leukemia with all-trans retinoic acid: a case, followed by conventional post-remission chemotherapy in complete remission].
Tsukada T; Mahmud N; Taniguchi M; Takahashi T; Kihira H; Kita K; Kobayashi T; Deguchi K; Shirakawa S
Rinsho Ketsueki; 1992 Dec; 33(12):1880-3. PubMed ID: 1479702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
